The two peptides everyone runs together for recovery, what each actually does, why they're paired, and the honest status of both. No hype, no hedging.
Studied for soft-tissue and gut-lining repair support.
Grade D, animal-dominant, fewer than 30 humans, no placebo-controlled efficacy trials.
Fewer than 30 humans have been studied, with no placebo-controlled efficacy trials. Long-term safety is uncharacterized.
Researched for tendon and muscle recovery support, typically paired with BPC-157.
Grade D, animal-dominant; the marketed fragment isn't trial-grade thymosin β4.
Human evidence is minimal and animal-dominant; the marketed fragment differs from studied Tβ4, and antibody responses have been raised.
The theory behind the stack is complementary, not redundant. BPC-157 works the gut-and-soft-tissue angle, proposed to support angiogenesis and tissue-repair signaling. TB-500 works the soft-tissue and cell-migration angle, a thymosin β4 fragment proposed to influence actin regulation. Run together, the idea is broader coverage of a stubborn recovery problem; that's why nearly every recovery conversation names both in the same breath.
Be clear-eyed: both sit at evidence grade D, both are animal-dominant, and TB-500's marketed fragment isn't trial-grade thymosin β4 (with immunogenicity questions raised). Pairing two grade-D peptides doesn't double the evidence, it stacks two uncertainties. Both are under the same FDA review, and neither is available to prescribe today.